Gunderson Dettmer represented client Affinivax, a clinical stage biopharmaceutical company, in its $226 million Series C financing co-led by Rock Springs Capital and Foresite Capital.

In the announcement of the transaction, CEO of Affinivax Steve Brugger said, “We are very pleased to welcome Rock Springs Capital, Foresite Capital, and this high-quality group of new investors to Affinivax who share our bold and global vision for the company. In addition to recognizing what we have already accomplished in advancing our MAPS platform to clinical validation, their strong commitment will support our aim to advance a new class of vaccines to protect children and adults against many challenging and resistant infectious diseases.”

The Gunderson deal team was led by Tim Ehrlich and included Jeff Vetter, Jay Hachigian, Keith Scherer, Erik Thompson, Beatrice Igne-Bianchi, Gabriella Stearns, John Maciejewski, and Camil Miki Zaganjor.